Evidence map›Paper›PMID 37070480›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2023

Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors.

D Zelencova-Gopejenko, V Andrianov, I Domracheva, I Kanepe-Lapsa, M Milczarek, M Stojak, K Przyborowski, F A Fedak, M Walczak, K Kramkowski and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

D Zelencova-GopejenkoLaboratory of Physical Organic Chemistry, Latvian Institute of Organic Synthesis, Riga, Latvia.
V AndrianovLaboratory of Carbofunctional Compounds, Latvian Institute of Organic Synthesis, Riga, Latvia.
I DomrachevaGroup of Experimental Chemical Therapy, Latvian Institute of Organic Synthesis, Riga, Latvia.
I Kanepe-LapsaGroup of Experimental Chemical Therapy, Latvian Institute of Organic Synthesis, Riga, Latvia.
M MilczarekDepartment of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
M StojakJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.
K PrzyborowskiJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.
F A FedakJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.
M WalczakJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.
K KramkowskiDepartment of Physical Chemistry, Medical University of Bialystok, Bialystok, Poland.
J WietrzykDepartment of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
S ChlopickiJagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland.
I KalvinsLaboratory of Carbofunctional Compounds, Latvian Institute of Organic Synthesis, Riga, Latvia.
Jagiellonian University · PLInstitute of Organic Synthesis · RULatvijas Organiskās Sintēzes Institūts · LVLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PLMedical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we report a series of newly synthesised sulphonamides of aziridine-2-carboxylic acid (Az-COOH) ester and amide analogues as potent protein disulphide isomerase (PDI, EC 5.3.4.1) inhibitors. The inhibitory activity on PDI was determined against recombinant human PDIA1 and PDIA3 proteins using an insulin reduction assay. These compounds in low micromolar to low nanomolar concentrations showed the effective

Indexed as

AziridinesProtein Disulfide-IsomerasesSulfonamidesHumansProcollagen-Proline Dioxygenaseaziridine-2-carboxylic acidAziridinesP4HB protein, humanPDIA3 protein, humanProcollagen-Proline DioxygenaseProtein Disulfide-IsomerasesSulfonamidesaziridineDisulphideinhibitorisomerasePDI

Identifiers

PMID37070480
PMCPMC10120451
OpenAlexW4366235408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.